The reasons behind the varied responses of the cells to PRO treatment might be due to variations in their features, in addition to other genetic and epigenetic factors, such as the mutation of the proto-oncogene (PIK3CA), the mutation of the apoptotic gene (TP53), microsatellite stability status (MSI), epigenetic alterations, the adrenergic receptor expression level, the type of adrenergic receptor expressed on the cell surface (ADRB 1, 2, or 3), the heterogeneity of cells, tumor origin, and duplicate growth time. Here, PIK3CA is linked to neoplasm.